Journal of Pharmacy Technology最新文献

{"title":"Impact of Incorporating Pharmacy Technicians Into a Clinical Pharmacy Workflow on Aspirin Prescribing in Patients With Ischemic Vascular Disease.","authors":"Licamied C Macklin, Morgan P Stewart, Kathryn P Lin, Leticia R Moczygemba, Leslie Simien","doi":"10.1177/87551225261458228","DOIUrl":"10.1177/87551225261458228","url":null,"abstract":"<p><strong>Background: </strong>Federally qualified health centers (FQHCs) use core quality measures to guide care and secure funding. One core measure is \"Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet.\" A pilot program at an FQHC utilized the clinical pharmacy team to improve appropriate aspirin prescribing. Clinical pharmacy technicians identified eligible patients through a best practice advisory (BPA) in the electronic health record and contacted individuals with IVD not prescribed aspirin to schedule a clinical pharmacist appointment. Pharmacists then conducted medication reconciliations and ordered aspirin when indicated. This study evaluated the impact of incorporating pharmacy technicians into the clinical pharmacy workflow on the IVD quality measure.</p><p><strong>Methods: </strong>This retrospective chart review compared aspirin prescriptions ordered from June to November 2023 between patients contacted by pharmacy technicians and those who were not. Demographics, outreach attempts, aspirin orders, and diagnosis codes were collected. Descriptive statistics and Fisher's exact test were used for analysis.</p><p><strong>Results: </strong>Pharmacy technicians attempted to contact 65 eligible patients, with 49 successfully reached. Aspirin was prescribed for 3.1% of control patients vs 30.6% in patients successfully contacted by the pharmacy team (<i>P</i> < .001). Resolved BPAs increased to 53.8% in the intervention group.</p><p><strong>Conclusion: </strong>A clinical pharmacy team significantly increased aspirin therapy among eligible patients with IVD, demonstrating the value of pharmacy team involvement on quality metrics. Future research should explore expanded integration of clinical pharmacy team services to enhance patient care.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261458228"},"PeriodicalIF":1.5,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azole Antifungal Prophylaxis of Invasive Fungal Infections in Immunocompromised Patients: Questions and Answers for Pharmacists.","authors":"Jacob M Kupetz, Kevin N Standen, Loulwa Maktabi, Justin P Reinert","doi":"10.1177/87551225261459921","DOIUrl":"10.1177/87551225261459921","url":null,"abstract":"<p><strong>Objective: </strong>To review the efficacy, safety, and clinical selection considerations of azole antifungal agents for prophylaxis of invasive fungal infections (IFIs) in immunocompromised patients using a clinically oriented, pharmacist-focused framework.</p><p><strong>Data sources: </strong>A literature review was conducted using PubMed and Embase to identify relevant studies evaluating azole antifungal prophylaxis in immunocompromised adult populations. Search terms included combinations of \"azole,\" \"antifungal prophylaxis,\" \"immunocompromised,\" and \"invasive fungal infection,\" with emphasis on contemporary studies reflecting current prophylaxis practices.</p><p><strong>Study selection and data extraction: </strong>Studies were included if they evaluated prophylactic use of azole antifungal agents in immunocompromised adults, including patients with hematologic malignancies, hematopoietic stem cell transplantation, or other defined immunocompromised states. Studies focused on treatment rather than prophylaxis, non-azole agents, pediatric populations, or lacking relevant clinical outcomes were excluded. Data extracted included study design, patient population, antifungal agent and dosing, incidence of IFIs, and reported safety outcomes.</p><p><strong>Data synthesis: </strong>Randomized controlled trials and observational studies demonstrate that azole antifungal prophylaxis significantly reduces IFI incidence in high-risk immunocompromised populations. Posaconazole has demonstrated superiority over fluconazole and itraconazole in neutropenic leukemia populations, while mold-active azoles including voriconazole and isavuconazole offer expanded prophylactic options in select patients. Therapeutic drug monitoring, drug interaction management, and individualized risk stratification are critical pharmacist-driven components of care. Safety findings remain consistent with known azole-associated toxicities including hepatotoxicity, QT interval alterations, neuropsychiatric effects, and cytochrome P450-mediated drug interactions.</p><p><strong>Conclusions: </strong>Azole antifungal prophylaxis remains a cornerstone strategy for prevention of IFIs in immunocompromised patients. Current evidence supports individualized, risk-based selection of prophylactic agents based on patient-specific risk factors rather than universal application of a single regimen. Pharmacists play a central role in optimizing prophylaxis through therapeutic drug monitoring, medication reconciliation, and toxicity mitigation. Additional studies are needed to optimize prophylaxis strategies and improve patient outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261459921"},"PeriodicalIF":1.5,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Pharmacy-Driven (1,3)-β-D-Glucan Algorithm on Micafungin Duration of Therapy in the ICU.","authors":"Daniella J Abi Kheir, Kevin Moriles, Amy L Carr, Yiyang Zhang, Kristin Sniffen, Jose Alexander, Arnaldo Lopez-Ruiz, Jason Sniffen, Patricia R Louzon","doi":"10.1177/87551225261446911","DOIUrl":"https://doi.org/10.1177/87551225261446911","url":null,"abstract":"<p><p><b>Background:</b> The (1,3)-β-D-glucan (BDG) test can be used as a stewardship approach to decrease antifungal overutilization, development of resistance, and excess costs. <b>Objective:</b> This study assessed the impact that a BDG algorithm has on micafungin duration of therapy (DOT) compared to standard of care (SOC). <b>Methods:</b> This retrospective, multisite, pre-post cohort study at a tertiary health system included nonneutropenic critically ill adults on empiric micafungin with risk factors for invasive candidiasis (IC). A BDG algorithm was utilized and compared to SOC for micafungin DOT. Secondary outcomes included length of stay (LOS), mortality, 30-day readmissions, cost, and BDG performance. <b>Results:</b> A total of 110 patients were included, with 55 patients per group. Overall, micafungin DOT was not different (94.7 [45.0-146.3] vs 95.4 [49.2-206.4] hours; P = .84) but was significantly shorter when BDG resulted within 48 hours (53.0 [46.1-98.1] vs 140.7 [72.8-226.6] hours; P = .014) or with algorithm compliance following negative results (47.6 [35.6-68.8] vs 94.7 [45.0-146.3] hours; P = .005). The test had negative and positive predictive values of 96.6% and 11.5%, respectively, with dialysis patients most likely to correlate with false positives (phi = 0.40, 95% CI: 0.15-0.60, P = .002). Patients who were immunocompromised or underwent surgery had prolonged DOT. <b>Conclusion:</b> A pharmacy-driven BDG algorithm did not significantly decrease micafungin DOT except with BDG results within 48 hours or with algorithm compliance following negative results. The BDG test may have less impact in immunocompromised, surgery, and dialysis patients. This highlights the need for research in antifungal stewardship to optimize patient outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261446911"},"PeriodicalIF":1.3,"publicationDate":"2026-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13198531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication Adherence and Inhaler Use in Patients With Asthma Treated at a Specialized Tertiary Respiratory Hospital in Vietnam.","authors":"Khanh Kim Ly, Hoa Van Truong, Lien Bich Thi Vo, Huong-Thao Nguyen","doi":"10.1177/87551225261443880","DOIUrl":"https://doi.org/10.1177/87551225261443880","url":null,"abstract":"<p><p><b>Background:</b> Asthma is a common chronic respiratory disease, reducing the quality of life and increasing the mortality risk of patients. Medication adherence and proper inhaler technique play an important role in asthma control. <b>Objective:</b> To investigate medication adherence, inhaler use, asthma control level, and its related factors among asthma outpatients treated at a specialized tertiary respiratory hospital. <b>Methods:</b> A descriptive cross-sectional study was conducted on asthma outpatients treated at the specialized respiratory hospital (April 1, 2022-June 30, 2022). Medication adherence, inhaler use, and asthma control were assessed using the General Medication Adherence Scale, content-validated checklists, and the asthma control test. Data were analyzed using SPSS software, <i>P</i> value of < 0.05 was considered statistically significant.<b>Results:</b> There were 184 patients included (mean age 48.86 ± 13.28, females 53.8%). More than half of the patients had at least one comorbidity (mainly allergic rhinitis). All patients were prescribed inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) as controller medications, and the most prescribed combination was ICS-LABA + leukotriene receptor antagonist (66.8%). The rates of patients with high medication adherence, proper inhaler technique, and good asthma control were 89.6%, 67.4%, and 75.0%, respectively. The higher medication adherence was associated with better asthma control (odds ratio = 4.584, 95% confidence interval 1.633-12.870, <i>P</i> = 0.004). Small sample size and single-center study may limit the generalizability of the results. <b>Conclusions:</b> Medication adherence was generally high, whereas inhaler technique errors remained common. Despite overall favorable asthma control, ongoing inhaler technique counseling and sustained medication adherence remain essential.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261443880"},"PeriodicalIF":1.3,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evaluation of Eravacycline Utilization for Infections Caused by Difficult-to-Treat Pathogens.","authors":"Daniel T Anderson, Joshua Eudy","doi":"10.1177/87551225261448487","DOIUrl":"https://doi.org/10.1177/87551225261448487","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Eravacycline is a fluorocycline with activity against multidrug-resistant (MDR) and difficult-to-treat (DTR) pathogens, but real-world outcome data are lacking for the treatment of infections caused by these organisms. The objective of this study was to evaluate the efficacy and safety of eravacycline for infections caused by MDR and/or DTR organisms. <b>Methods:</b> This was a retrospective, observational study of adult patients receiving eravacycline for at least 72 hours for MDR or DTR organisms. The primary outcome was 30-day mortality. Secondary outcomes included 60-day relapse, 30-day readmission, and adverse drug events (ADEs). <b>Results:</b> A total of 17 patients were included in the analysis. The cohort had a high baseline mortality risk (median Charlson Comorbidity Index of 5). Osteoarticular infections were the most common indication (52.9%). The most frequently isolated pathogens were <i>Enterococcus</i> spp. and <i>Enterobacterales</i> spp. (58.9% each). Most infections were polymicrobial. Eravacycline minimum inhibitory concentrations (MIC) were available in only 47% of cases, and the median time to treatment initiation was 6 days after culture collection. Thirty-day all-cause mortality occurred in 17.6% of patients. Among survivors, 60-day relapse and 30-day readmission were low (6% each). The ADEs occurred in 35% of patients but led to no discontinuations. <b>Conclusions:</b> In this cohort of severely ill patients with complex, predominantly polymicrobial MDR and DTR infections, eravacycline demonstrated favorable safety and efficacy results despite delays from index culture to initiation of targeted therapy. These data suggest eravacycline may be a viable treatment option for infections caused by MDR and DTR organisms.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261448487"},"PeriodicalIF":1.3,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticholinergic Adverse Effects Associated With Skeletal Muscle Relaxants in the Intensive Care Unit.","authors":"Justin P Reinert, Jordyn Maroszek, Rose Sikorski","doi":"10.1177/87551225261446913","DOIUrl":"https://doi.org/10.1177/87551225261446913","url":null,"abstract":"<p><p><b>Background</b>: Pain is prevalent among critically ill patients and is frequently underrecognized due to sedation and mechanical ventilation. Opioids remain the primary analgesic therapy in the intensive care unit (ICU); however, opioid-related adverse effects have prompted increased adoption of multimodal analgesia strategies. Centrally acting skeletal muscle relaxants, including cyclobenzaprine and methocarbamol, are commonly used as adjuncts, yet data evaluating their anticholinergic adverse effects in critically ill populations are limited. <b>Methods</b>: The primary objective of this study is to determine the prevalence of anticholinergic adverse drug events (ADEs) associated with cyclobenzaprine and methocarbamol among ICU patients. <b>Purpose</b>: This retrospective cohort study evaluated adult patients (≥18 years) admitted to any ICU at a single academic medical center between January 1, 2023 and January 31, 2025, who received at least 1 dose of cyclobenzaprine or methocarbamol during ICU admission. The primary outcome was the prevalence of anticholinergic ADEs, identified through provider documentation and <i>International Classification of Diseases, Tenth Revision</i> (<i>ICD-10</i>) codes. Secondary outcomes included types of ADEs, dosing of the study drugs, and medication discontinuation rates. <b>Results</b>: Of 367 eligible patients, 260 were included in the final analysis. Cyclobenzaprine was administered to 112 patients (43%) and methocarbamol to 148 patients (57%). Potential anticholinergic ADEs were identified in 29 patients (14.4%) receiving cyclobenzaprine and 17 patients (10.8%) receiving methocarbamol. Among the 69 total ADEs, 55 (79%) prompted an intervention, most commonly pharmacologic therapy adjustments. Medication discontinuation due to ADEs was infrequent. <b>Conclusions</b>: Cyclobenzaprine and methocarbamol were associated with anticholinergic adverse effects in critically ill ICU patients, though this did not translate to medication discontinuation. These findings support the cautious use of centrally acting muscle relaxants as part of multimodal analgesia strategies. Pharmacists are uniquely positioned to evaluate and mitigate adverse drug effects in the critically ill.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261446913"},"PeriodicalIF":1.3,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Clinical Pharmacist on Weight Loss Outcomes in Primary Care Patients Without Diabetes.","authors":"Kayla Sturtevant, Marci Wood, Juvena R Hitt, Amanda G Kennedy, Halle G Sobel","doi":"10.1177/87551225261443443","DOIUrl":"10.1177/87551225261443443","url":null,"abstract":"<p><p><b>Background:</b> Obesity is a prevalent condition associated with numerous comorbidities. Weight loss medications reduce comorbidity burden, but barriers hinder access and titration. Clinical pharmacists play a key role in chronic disease management, but limited research exists on pharmacists managing weight loss. <b>Objective:</b> Evaluate the impact of a clinical pharmacist on weight loss medication management for adults without diabetes in an outpatient Internal Medicine primary care resident clinic. <b>Methods:</b> This matched case-control study included adults without diabetes with at least 1 weight management visit with a clinical pharmacist between July 2023 and May 2024. Controls were matched on insurance and baseline body mass index, and included patients prescribed weight loss medications by clinicians and those without pharmacotherapy. Data were collected over 6 months. The primary outcome was percent weight loss. Rate of weight loss was explored as a secondary outcome. <b>Results:</b> 94 patients were included: 35 pharmacist-managed, 24 clinician-managed, and 35 without pharmacotherapy. At 6 months, mean weight change was -11.8%, -8.3%, and +1.3% in the pharmacist, clinician, and nonmedication groups, respectively. Absolute weight loss was greater in the pharmacist group, but not statistically significant compared with the clinician-managed group (<i>P</i> = 0.12). The weekly rate of weight loss was significantly higher in the pharmacist group (-0.29 kg/week; <i>P</i> = 0.04 and <i>P</i> < 0.001 vs controls). <b>Conclusion:</b> Patients prescribed obesity medications experienced significant weight loss, regardless of whether the patients were managed by pharmacists or primary care clinicians. These findings support a collaborative care model in obesity management.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261443443"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Direct Oral Anticoagulants Compared to Warfarin in Patients With Body Mass Index ≥40 kg/m² in a Real-World Setting.","authors":"Kiara Bautista, Anisa Bici, Denise Sutter-Long, Elizabeth Liza Renner, Erin Mouland, Mary Jo Elder, Nhan Hoang, Amir Farid, Nghi Ha","doi":"10.1177/87551225261445649","DOIUrl":"https://doi.org/10.1177/87551225261445649","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) and venous thromboembolism (VTE) are common conditions requiring anticoagulation in patients with severe obesity (body mass index ≥40 kg/m²). Comparative safety and efficacy data for direct oral anticoagulants (DOACs) vs warfarin in this population remain limited.</p><p><strong>Objective: </strong>To compare the safety and efficacy of DOACs and warfarin in non-valvular atrial fibrillation (NVAF) and VTE in patients with severe obesity in a real-world setting.</p><p><strong>Methods: </strong>This single-center, retrospective matched cohort study included adults with severe obesity receiving a DOAC or warfarin for NVAF or VTE from January 1, 2019, to December 31, 2024. Patients were matched by age, sex, and indication. Primary outcomes were composite thrombotic events (recurrent VTE or ischemic stroke occurrence) and composite bleeding events (clinically relevant non-major and major bleed). Secondary outcomes were assessments of predictors for these events.</p><p><strong>Results: </strong>The study included 182 patients, 91 per cohort. Composite bleeding was significantly higher in the warfarin group (39.6% vs 23.1%, <i>P</i> = 0.017), but it was not significantly different after adjustment for time on therapy. Composite thrombotic events were similar between groups (12.1% vs 9.9%, <i>P</i> = 0.89). History of major bleed (hazard ratio [HR] = 2.37, <i>P</i> = 0.022, 95% confidence interval [CI] = [1.13-4.96]) and concomitant antiplatelet use (HR = 3.80, <i>P</i> < 0.001, 95% CI = [1.98-7.26]) were predictors for bleeding. History of cerebrovascular accident (CVA)/transient ischemic attack (TIA) (HR = 3.34, <i>P</i> = 0.014, 95% CI = [1.28-8.74]) was a predictor for thrombosis.</p><p><strong>Conclusion: </strong>DOACs demonstrated comparable safety and efficacy to warfarin in patients with severe obesity with NVAF or VTE.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261445649"},"PeriodicalIF":1.3,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior Reversible Encephalopathy Syndrome (PRES) Associated With Lenvatinib: A Disproportionality Analysis.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/87551225261446468","DOIUrl":"https://doi.org/10.1177/87551225261446468","url":null,"abstract":"<p><strong>Background: </strong>Posterior reversible encephalopathy syndrome (PRES) is a rare but potentially life-threatening neurological condition characterized by seizures, headache, visual disturbances, and altered mental status, typically associated with vasogenic edema on neuroimaging. Although several anticancer therapies have been implicated in PRES, evidence regarding its association with lenvatinib remains limited.</p><p><strong>Purpose: </strong>The aim of this study was to investigate a potential safety signal between lenvatinib and PRES using a pharmacovigilance approach and evaluate whether reports of PRES are disproportionately associated with lenvatinib in a large spontaneous reporting database.</p><p><strong>Methods: </strong>A retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System (FAERS) database. Individual Case Safety Reports (ICSRs) mentioning lenvatinib and PRES were identified and extracted. Disproportionality analysis was performed by calculating the reporting odds ratio (ROR), proportional reporting ratio (PRR), and chi-square statistic. According to Evans' criteria (n > 2, PRR > 2, chi-square > 4), a drug-event combination is considered suggestive of a potential safety signal.</p><p><strong>Results: </strong>The disproportionality analysis revealed a statistically significant signal for PRES associated with lenvatinib. The PRR was 5.79 (95% CI: 4.80-6.98), and the ROR was 5.81 (95% CI: 4.81-7.00), both exceeding commonly accepted signal detection thresholds. These findings suggest that reports of PRES occur more frequently with lenvatinib than with other drugs in the database.</p><p><strong>Conclusion: </strong>This pharmacovigilance analysis identified a significant disproportionality signal suggesting a potential association between lenvatinib and PRES. Although spontaneous reporting systems cannot establish causality, these findings highlight the importance of clinical awareness and further investigation to better characterize this rare but serious adverse event.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261446468"},"PeriodicalIF":1.3,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of Cefiderocol in a Case of Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> Prostatitis and Recurrent Urinary Tract Infection.","authors":"Nicole Sunshine, Rachel M Kenney, Nathan A Everson, Anita B Shallal, Michael P Veve","doi":"10.1177/87551225261443444","DOIUrl":"https://doi.org/10.1177/87551225261443444","url":null,"abstract":"<p><p>Treatment of extensively drug-resistant (XDR) organisms is complicated by pharmacodynamic and pharmacokinetic (PK) limitations of current antimicrobial agents. Prostatitis is an infection that is historically difficult to treat with beta-lactams given poor tissue penetration as compared to fluoroquinolones and sulfamethoxazole-trimethoprim. Cefiderocol is a novel cephalosporin that is often used to treat a wide variety of gram-negative bacteria that have extensive resistance to other antibiotics. Cefiderocol remains stable against many β-lactamases and shows enhanced bacterial cell entry as a result of siderophore uptake. However, its penetration into prostatic tissue has not been studied. This review presents the use of cefiderocol in a patient with complicated urinary tract infection and prostatitis caused by XDR <i>Klebsiella pneumoniae</i> resistant to almost all tested antibiotics, including novel beta-lactam/beta-lactamase combinations. Although PK data suggest that cefiderocol may achieve therapeutic concentrations in prostatic tissue, further studies are needed to confirm its efficacy in treating prostatitis, particularly in cases of chronic or complicated infection. This case highlights cefiderocol as a potential therapeutic option for XDR <i>Enterobacterales</i> prostatitis, though additional research is required to fully understand its prostate penetration and clinical outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261443444"},"PeriodicalIF":1.3,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147816353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}